A Post-marketing, Observational Safety Study of Quinsair (Levofloxacin Hemihydrate) in Patients with Cystic Fibrosis [CLI-LEVFLAA1-01]

20/09/2017
13/04/2026
EU PAS number:
EUPAS20990
Study
Finalised
Subscribe
Download as PDF
Documents
Study protocol
Updated protocol

Quinsair PASS redacted study protocol_v 5.0_13Oct2022_redacted.pdf

First published: 10/04/2026
English (2.31 MB - PDF) View document
Study results
Study results

Quinsair PASS abstract publication.pdf

English (168.97 KB - PDF) View document
Study report
Other information